Mark Butler’s four 'pillars' on medicines policy and the argument that Australia prioritises low prices over preventing shortages and ensuring access. Do we need smarter, targeted incentives to address shortages that often reflect global challenges? Is there a risk of 'process creep' that actually slows access? Aged-care reforms that unintentionally removed funding for dose administration aids and glucose monitoring.
Latest Video
New Stories
-
Australian dementia experts push back on Cochrane Review, defending new treatments
April 20, 2026 - - Latest News -
Australia’s drug pricing dogma risks failing patients in the face of international realities
April 20, 2026 - - Latest News -
Free RSV vaccines roll out to protect senior Australians ahead of winter
April 20, 2026 - - Latest News -
Alterity strengthens board with seasoned biotech leader as it advances flagship therapy
April 19, 2026 - -
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News
